24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

24/7 MN – (NASDAQ: ANVS) wins FDA approval for late state Parkinson’s candidate. Shares are also up 22% $16.22 this morning on 5100 shares. And closing in on half a million shares in volume

FDA Allows Annovis Bio To Proceed With Phase 3 Study Of Buntanetap In Parkinson’s Disease

RelatedNews

24/7 MN – (NASDAQ: ANVS) wins FDA approval for late state Parkinson’s candidate. Shares are also up 22% $16.22 this morning on 5100 shares. And closing in on half a million shares in volume

Want more news like this? Check out our homepage!

Recent News

Dermata Therapeutics Volume Alert

DiamondHead Holdings hits New 52-week High Following Yesterday’s PIPE Investment News

ZyVersa Therapeutics Higher in Premarket Trading

T2 Biosystems Plans to Add Candida Auris Detection to T2Candida Panel

SQZ Biotechnologies Confirms Complete Response in Clinical Trial

Follow Us

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Search by keyword

Add New Playlist